Skip to main content

FDA Approves Tablet Form of Evrysdi for Spinal Muscular Atrophy

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 18, 2025.

By Lori Solomon HealthDay Reporter

TUESDAY, Feb. 18, 2025 -- The U.S. Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for people living with spinal muscular atrophy (SMA).

The new tablet is expected to be available in the coming weeks and is suitable for people aged 2 years and older who weigh more than 44 lbs.

The approval of the Evrysdi tablet was based on the results of a bioequivalence study, which demonstrated that the 5-mg tablet, either swallowed whole or dispersed in filtered water, provided comparable exposure to the original oral solution of Evrysdi. The Evrysdi oral solution will remain available for those on other doses of Evrysdi and for those who may prefer the oral solution.

"We cannot underestimate the value that comes with simplifying treatment administration and disease management for people who are living with SMA or those caring for them," Kenneth Hobby, president of Cure SMA, said in a statement. "This new room temperature stable formulation option offers an additional choice that may more conveniently fit into daily living activities such as working, traveling, and education."

Approval of Evrysdi was granted to Genentech.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted February 2025

Read this next

Link Between T2DM, Spinal Degenerative Disorder May Be Method-Dependent

TUESDAY, July 23, 2024 -- The association between type 2 diabetes mellitus (T2DM) and spinal degenerative disorders (SDDs) may be method-dependent, according to a study published...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.